Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.

Criss SD, Mooradian MJ, Watson TR, Gainor JF, Reynolds KL, Kong CY.

JAMA Netw Open. 2019 Sep 4;2(9):e1911952. doi: 10.1001/jamanetworkopen.2019.11952.

2.

Pembrolizumab in lung cancer: current evidence and future perspectives.

Palumbo G, Carillio G, Manzo A, Montanino A, Sforza V, Costanzo R, Sandomenico C, Manna C, Luca G, Piccirillo MC, Daniele G, Cecio R, Botti G, Totaro G, Muto P, Picone C, Esposito G, Normanno N, Morabito A.

Future Oncol. 2019 Oct;15(29):3327-3336. doi: 10.2217/fon-2019-0073. Epub 2019 Aug 21.

PMID:
31432705
3.

Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.

Melosky B, Juergens R, Hirsh V, McLeod D, Leighl N, Tsao MS, Card PB, Chu Q.

Oncologist. 2019 May 28. pii: theoncologist.2019-0027. doi: 10.1634/theoncologist.2019-0027. [Epub ahead of print]

PMID:
31138727
4.

Chemo-immunotherapy: The Beginning of a New Era in Lung Cancer.

Uprety D.

Clin Lung Cancer. 2019 Mar;20(2):63-65. doi: 10.1016/j.cllc.2018.11.006. Epub 2018 Nov 22. No abstract available.

PMID:
30545572
5.

Moving away (finally) from doublet therapy in lung cancer: immunotherapy and KEYNOTE-189.

Sheela S, Kim ES, Mileham KF.

J Thorac Dis. 2018 Sep;10(9):5186-5189. doi: 10.21037/jtd.2018.09.05. No abstract available.

6.

Pembrolizumab for the first-line treatment of non-small cell lung cancer.

Ninomiya K, Hotta K.

Expert Opin Biol Ther. 2018 Oct;18(10):1015-1021. doi: 10.1080/14712598.2018.1522300. Epub 2018 Sep 19. Review.

PMID:
30207786
7.

Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.

Insinga RP, Vanness DJ, Feliciano JL, Vandormael K, Traore S, Burke T.

J Med Econ. 2018 Dec;21(12):1191-1205. doi: 10.1080/13696998.2018.1521416. Epub 2018 Sep 21.

PMID:
30188231
8.

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators.

N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.

Supplemental Content

Loading ...
Support Center